<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551782</url>
  </required_header>
  <id_info>
    <org_study_id>CR108476</org_study_id>
    <secondary_id>2018-000182-37</secondary_id>
    <secondary_id>56021927PCR2032</secondary_id>
    <nct_id>NCT03551782</nct_id>
  </id_info>
  <brief_title>A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination With Apalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the combination of cetrelimab, with&#xD;
      apalutamide and to define a population of participants with metastatic castration-resistant&#xD;
      prostate cancer (mCRPC) who respond to treatment with the combination of cetrelimab and&#xD;
      apalutamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is of participants originally diagnosed with adenocarcinoma of the prostate who&#xD;
      have now developed mCRPC and who have progressed on therapy with abiraterone acetate plus&#xD;
      prednisone/prednisolone (AA-P), apalutamide, darolutamide, or enzalutamide. Participants with&#xD;
      treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) assessed by the&#xD;
      screening biopsy may be considered for this study. Participants must have confirmed&#xD;
      prostate-specific antigen (PSA) progression per Prostate Cancer Clinical Trials Working Group&#xD;
      (PCWG3) criteria. The primary hypothesis is that treatment with cetrelimab and apalutamide is&#xD;
      safe and leads to improvement in the 12-week PSA response rate. The study consists of an&#xD;
      Optional Pre-screening Period, Screening period (28 days prior to Cycle 1 Day 1), Treatment&#xD;
      Period, End-of-Treatment Visit (performed after the last dose of study drug is administered),&#xD;
      and Follow-up Period (participants will have Follow-up assessment every 12 weeks after the&#xD;
      End-of-Treatment Visit). The efficacy, safety, and pharmacokinetics of cetrelimab in&#xD;
      combination with apalutamide will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Anticipated">June 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with AEs by Severity</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Severity of AEs will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Any AE not listed in the NCI CTCAE will be graded according to the investigator clinical judgment by using the standard grades as follows: Grade 1 Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities; Grade 2 Moderate: Sufficient discomfort is present to cause interference with normal activity; Grade 3 Severe: Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities; Grade 4: Life-threatening or disabling AE; Grade 5: Death related to the AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Prostate-Specific Antigen (PSA) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of participants with baseline in PSA level response (greater than or equal to [&gt;=]50 percent [%] decrease from baseline in PSA) will be reported at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal PSA Decline</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Maximal PSA decline is defined as maximal percent decrease in PSA at any time during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Circulating Tumor Cell (CTC) Response</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Percentage of participants with CTC response (either CTC less than [&lt;]5 cells/7.5 milliliter [mL] with CTC &gt;=5 at baseline or CTC = 0 cells/7.5 mL with CTC &gt;=1 at baseline) will be reported.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Castration-Resistant Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not treatment-emergent small-cell neuroendocrine prostate cancer [t-SCNC]) who progressed on abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive cetrelimab 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biomarker-positive participants who progressed on AA-P will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biomarker-positive participants who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biomarker-negative participants with t-SCNC who progressed on treatment with AA-P, apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrelimab 480 mg</intervention_name>
    <description>Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>JNJ-63723283</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide 240 mg</intervention_name>
    <description>Apalutamide 240 mg (4*60 mg) tablets per day will be administered orally.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed adenocarcinoma of the prostate. Treatment-emergent small-cell&#xD;
             neuroendocrine prostate cancer (t-SCNC) on screening biopsy may be eligible for cohort&#xD;
             5&#xD;
&#xD;
          -  Metastatic disease as documented by technetium-99m (99mTc) bone scan or metastatic&#xD;
             lesions by computed tomography (CT) or magnetic resonance imaging (MRI) scans&#xD;
             (visceral or lymph node disease). CT-portion of positron emission tomography (PET)/CT&#xD;
             scan may be used for eligibility. If lymph node metastasis is the only evidence of&#xD;
             metastatic disease, it must be greater than (&gt;=) 1.0 centimeter (cm) in the short axis&#xD;
             and above the level of the iliac bifurcation&#xD;
&#xD;
          -  Progressed while on therapy with abiraterone acetate plus prednisone/prednisolone&#xD;
             (AA-P), enzalutamide, darolutamide, or apalutamide for mCRPC. No washout is required&#xD;
             and no additional therapy may have been administered between discontinuation of&#xD;
             AR-targeted the agent and study treatment. Participants will be assigned to cohorts&#xD;
             based on the results of the biomarker panel. Cohort 1: Biomarker-negative or&#xD;
             biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed on&#xD;
             abiraterone acetate plus prednisone/prednisolone (AA-P); Cohort 2: Biomarker-negative&#xD;
             or biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed&#xD;
             on apalutamide, darolutamide, or enzalutamide; Cohort 3: Biomarker-positive&#xD;
             participants who progressed on AA-P; Cohort 4: Biomarker-positive participants who&#xD;
             progressed on apalutamide, darolutamide, or enzalutamide; Cohort 5: Biomarker-negative&#xD;
             participants with t-SCNC who progressed on treatment with AA-P, apalutamide,&#xD;
             darolutamide, or enzalutamide&#xD;
&#xD;
          -  Surgical or medical castration, with testosterone levels of less than (&lt;)50 nanogram&#xD;
             per deciliter (ng/dL). If the participant is being treated with gonadotropin-releasing&#xD;
             hormone (GnRH) analogs (participant who has not undergone bilateral orchiectomy), this&#xD;
             therapy must have been initiated at least 4 weeks prior to first dose of study drug&#xD;
             and must be continued throughout the study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG) prostate-specific (PS)&#xD;
             grade of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Initial diagnosis of primary prostatic neuroendocrine or small cell carcinoma&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Prior treatment with an anti-programmed cell death receptor-1 (PD-1), anti-programmed&#xD;
             cell death ligand 1 (PD-L1), or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4)&#xD;
             antibody&#xD;
&#xD;
          -  Prior chemotherapy, except for docetaxel for hormone-sensitive prostate cancer (HSPC)&#xD;
&#xD;
          -  Prior therapy with poly adenosine diphosphate (ADP)-ribose polymerase (PARP)&#xD;
             inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco (UCSF) - Prostate Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158-2350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Bay Saint Louis</city>
        <state>Mississippi</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute, Carolinas HealthCare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centers for Advanced Urology, LLC; d/b/a MidLantic Urology</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi, site Notre Dame</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia Servizio Radioterapia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKI-AVL, Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital # 62</name>
      <address>
        <city>Moscow</city>
        <zip>125130</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hertzen Oncology Research Institute</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Healthcare Institution 'Road Clinical Hospital of Russian Railways'</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Scientific Center of Radiology and Surgical Technologies</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Fund. Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Hm Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen de La Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Quiron Madrid Pozuelo</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

